Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia

References

• Marcucci G, Haferlach T, Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29(5):475–486. doi:10.1200/JCO.2010.30.255421220609
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA-Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Jordan CT. Therapeutic targeting of acute myeloid leukemia stem cells. Blood. 2017;129(12):1627–1635. doi:10.1182/blood-2016-10-69603928159738
   PubMed Web of Science ®Google Scholar
• Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392(10147):593–606. doi:10.1016/S0140-6736(18)31041-930078459
   PubMed Web of Science ®Google Scholar
• Click ZR, Seddon AN, Bae YR, Fisher JD, Ogunniyi A. New food and drug administration-approved and emerging novel treatment options for acute myeloid leukemia. Pharmacotherapy. 2018;38(11):1143–1154. doi:10.1002/phar.218030220082
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11(6):543–552. doi:10.1016/S1470-2045(10)70090-520451454
   PubMed Web of Science ®Google Scholar
• Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther. 2005;4(2):139–163. doi:10.4161/cbt.4.2.150815725726
   PubMed Web of Science ®Google Scholar
• Kominami K, Nakabayashi J, Nagai T, et al. The molecular mechanism of apoptosis upon caspase-8 activation: quantitative experimental validation of a mathematical model. Biochim Biophys Acta. 2012;1823(10):1825–1840. doi:10.1016/j.bbamcr.2012.07.00322801217
   PubMed Web of Science ®Google Scholar
• Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495–516. doi:10.1080/0192623070132033717562483
   PubMed Web of Science ®Google Scholar
• Knight T, Luedtke D, Edwards H, Taub JW, Ge Y. A delicate balance - The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics. Biochem Pharmacol. 2019;162:250–261. doi:10.1016/j.bcp.2019.01.01530668936
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov. 2017;16(4):273–284. doi:10.1038/nrd.2016.25328209992
   PubMed Web of Science ®Google Scholar
• Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 2018;25(1):65–80. doi:10.1038/cdd.2017.18629149100
   PubMed Web of Science ®Google Scholar
• Potter DS, Letai A. To prime, or not to prime: that is the question. Cold Spring Harb Symp Quant Biol. 2016;81:131–140. doi:10.1101/sqb.2016.81.03084127811212
   PubMedGoogle Scholar
• Ni Chonghaile T, Sarosiek KA, Vo TT, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011;334(6059):1129–1133. doi:10.1126/science.120672722033517
   PubMed Web of Science ®Google Scholar
• Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435(7042):677–681. doi:10.1038/nature0357915902208
   PubMed Web of Science ®Google Scholar
• Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421–3428. doi:10.1158/0008-5472.CAN-07-583618451170
   PubMed Web of Science ®Google Scholar
• Vogler M, Walter HS, Dyer MJS. Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment. Br J Haematol. 2017;178(3):364–379. doi:10.1111/bjh.1468428449207
   PubMed Web of Science ®Google Scholar
• Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128(6):1173–1186. doi:10.1016/j.cell.2007.01.03717382885
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–208. doi:10.1038/nm.304823291630
   PubMed Web of Science ®Google Scholar
• Wilson WH, O’Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11(12):1149–1159. doi:10.1016/S1470-2045(10)70261-821094089
   PubMed Web of Science ®Google Scholar
• Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30(5):488–496. doi:10.1200/JCO.2011.34.789822184378
   PubMed Web of Science ®Google Scholar
• Kipps TJ, Eradat H, Grosicki S, et al. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015;56(10):2826–2833. doi:10.3109/10428194.2015.103063825797560
   PubMed Web of Science ®Google Scholar
• Jones AK, Freise KJ, Agarwal SK, Humerickhouse RA, Wong SL, Salem AH. Clinical predictors of venetoclax pharmacokinetics in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma patients: a pooled population pharmacokinetic analysis. AAPS J. 2016;18(5):1192–1202. doi:10.1208/s12248-016-9927-927233802
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322. doi:10.1056/NEJMoa151325726639348
   PubMed Web of Science ®Google Scholar
• Davids MS, Hallek M, Wierda W, et al. Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia. Clin Cancer Res. 2018;24(18):4371–4379. doi:10.1158/1078-0432.CCR-17-376129895707
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768–778. doi:10.1016/S1470-2045(16)30019-527178240
   PubMed Web of Science ®Google Scholar
• Seymour JF, Ma S, Brander DM, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017;18(2):230–240. doi:10.1016/S1470-2045(17)30012-828089635
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Morschhauser F, Wendtner CM, et al. Phase Ib Study (GO28440) of venetoclax with bendamustine/rituximab or bendamustine/obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia. Blood. 2016;128:22. doi:10.1182/blood-2016-06-724161
   Web of Science ®Google Scholar
• Cramer P, von Tresckow J, Bahlo J, et al. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(9):1215–1228. doi:10.1016/S1470-2045(18)30414-530115596
   PubMed Web of Science ®Google Scholar
• Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. New Engl J Med. 2018;378(12):1107–1120. doi:10.1056/NEJMoa171397629562156
   PubMed Web of Science ®Google Scholar
• El-Cheikh J, Moukalled NM, El Darsa H, et al. Feasibility of the combination of venetoclax and asparaginase-based chemotherapy for adult patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2018;18(10):e441–e444. doi:10.1016/j.clml.2018.07.28930166258
   PubMed Web of Science ®Google Scholar
• de Vos S, Swinnen LJ, Wang D, et al. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Ann Oncol. 2018;29(9):1932–1938. doi:10.1093/annonc/mdy25630060083
   PubMed Web of Science ®Google Scholar
• Rahbari KJ, Nosrati JD, Spektor TM, Berenson JR. Venetoclax in combination with bortezomib, dexamethasone, and daratumumab for multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018;18(9):e339–e343. doi:10.1016/j.clml.2018.06.00330033209
   PubMed Web of Science ®Google Scholar
• Moreau P, Chanan-Khan A, Roberts AW, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. 2017;130(22):2392–2400. doi:10.1182/blood-2017-06-78832328847998
   PubMed Web of Science ®Google Scholar
• Mihalyova J, Jelinek T, Growkova K, Hrdinka M, Simicek M, Hajek R. Venetoclax: A new wave in hematooncology. Exp Hematol. 2018;61:10–25. doi:10.1016/j.exphem.2018.02.00229477371
   PubMed Web of Science ®Google Scholar
• Jelinek T, Mihalyova J, Kascak M, et al. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14). Am J Hematol. 2019;94(1):E35–E37. doi:10.1002/ajh.2533130370955
   PubMed Web of Science ®Google Scholar
• Leung N, Thome SD, Dispenzieri A. Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone. Haematologica. 2018;103(3):e135–e137.29351984
   PubMed Web of Science ®Google Scholar
• Wei A, Strickland SA, Roboz GJ, et al. Safety and efficacy of venetoclax plus low-dose cytarabine in treatment-naive patients aged ≥ 65 years with acute myeloid leukemia. Blood. 2016;128:22. doi:10.1182/blood-2016-06-724161
   Web of Science ®Google Scholar
• Lin TL, Strickland SA, Fiedler W, et al. Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age ≥ 65 with acute myelogenous leukemia. J Clin Oncol. 2016;34(15_suppl):7007. doi:10.1200/JCO.2016.34.15_suppl.7007
   Web of Science ®Google Scholar
• Wei A, Strickland SA, Roboz GJ, et al. Phase 1/2 study of venetoclax with low-dose cytarabine in treatment-naive, elderly patients with acute myeloid leukemia unfit for intensive chemotherapy: 1-year outcomes. Blood. 2017;130.
   Web of Science ®Google Scholar
• Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109(6):1114–1124. doi:10.1002/cncr.2249617315155
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216–228. doi:10.1016/S1470-2045(18)30010-X29339097
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17. doi:10.1182/blood-2018-08-86875230361262
   PubMed Web of Science ®Google Scholar
• Cashen AF, Schiller GJ, O’Donnell MR, DiPersio JF. Multicenter, Phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010;28(4):556–561. doi:10.1200/JCO.2009.23.917820026803
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562–569. doi:10.1200/JCO.2009.23.832920026804
   PubMed Web of Science ®Google Scholar
• Venetoclax: Prescribing Information [Package Insert]. Chicago (IL): Abbvie Inc.; 2018.
   Google Scholar
• Agarwal SK, DiNardo CD, Potluri J, et al. Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther. 2017;39(2):359–367. doi:10.1016/j.clinthera.2017.01.00328161120
   PubMed Web of Science ®Google Scholar
• Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci. 2009;66(8):1326–1336. doi:10.1007/s00018-008-8637-619099185
   PubMed Web of Science ®Google Scholar
• Luedtke DA, Niu X, Pan Y, et al. Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Signal Transduct Target Ther. 2017;2:17012. doi:10.1038/sigtrans.2017.1229263915
   PubMed Web of Science ®Google Scholar
• Niu X, Zhao J, Ma J, et al. Binding of released bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells. Clin Cancer Res. 2016;22(17):4440–4451. doi:10.1158/1078-0432.CCR-15-305727103402
   PubMed Web of Science ®Google Scholar
• Yang-Yen HF. Mcl-1: a highly regulated cell death and survival controller. J Biomed Sci. 2006;13(2):201–204. doi:10.1007/s11373-005-9064-416456709
   PubMed Web of Science ®Google Scholar
• Kotschy A, Szlavik Z, Murray J, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538(7626):477–482. doi:10.1038/nature19830
   PubMed Web of Science ®Google Scholar
• Li Z, He S, Look AT. The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells. Leukemia. 2019;33(1):262–266.30008477
   PubMed Web of Science ®Google Scholar
• Ramsey HE, Fischer MA, Lee T, et al. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 2018;8(12):1566–1581. doi:10.1158/2159-8290.CD-18-014030185627
   PubMed Web of Science ®Google Scholar
• Morales F, Giordano A. Overview of CDK9 as a target in cancer research. Cell Cycle. 2016;15(4):519–527. doi:10.1080/15384101.2016.113818626766294
   PubMed Web of Science ®Google Scholar
• Boffo S, Damato A, Alfano L, Giordano A. CDK9 inhibitors in acute myeloid leukemia. J Exp Clin Cancer Res. 2018;37(1):36. doi:10.1186/s13046-018-0704-829471852
   PubMedGoogle Scholar
• Luedtke DA, Su YW, Liu S, et al. Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1. J Cell Mol Med. 2018;22(12):6099–6111. doi:10.1111/jcmm.1388630596398
   PubMed Web of Science ®Google Scholar
• Xie CZ, Edwards H, Caldwell JT, Wang G, Taub JW, Ge YB. Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage. Mol Oncol. 2015;9(2):409–421. doi:10.1016/j.molonc.2014.09.00825308513
   PubMed Web of Science ®Google Scholar
• Song T, Chai G, Liu Y, Yu X, Wang Z, Zhang Z. Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding. Br J Pharmacol. 2016;173(3):471–483. doi:10.1111/bph.1337026493374
   PubMed Web of Science ®Google Scholar
• Fresquet V, Rieger M, Carolis C, Garcia-Barchino MJ, Martinez-Climent JA. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood. 2014;123(26):4111–4119. doi:10.1182/blood-2014-03-56028424786774
   PubMed Web of Science ®Google Scholar
• Tahir SK, Smith ML, Hessler P, et al. Potential mechanisms of resistance to venetoclax and strategies to circumvent it. BMC Cancer. 2017;17(1):399. doi:10.1186/s12885-017-3383-528578655
   PubMedGoogle Scholar
• Mali RS, Lasater EA, Doyle K, et al. FLT3-ITD activation mediates resistance to the BCL-2 selective antagonist, venetoclax, in FLT3-ITD mutant AML models. Blood. 2017;130.
   Web of Science ®Google Scholar
• Pan RQ, Ruvolo VR, Wei J, et al. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Blood. 2015;126(3):363–372. doi:10.1182/blood-2014-10-60497526045609
   PubMed Web of Science ®Google Scholar
• De Grandis M, Mancini SJ, Aurrand-Lions M. In quest for leukemia initiating cells in AML. Oncoscience. 2018;5(1–2):9–10. doi:10.18632/oncoscience.39429556512
   PubMedGoogle Scholar
• Doan PL, Chute JP. The vascular niche: home for normal and malignant hematopoietic stem cells. Leukemia. 2012;26(1):54–62. doi:10.1038/leu.2011.23621886170
   PubMed Web of Science ®Google Scholar
• Ho TC, LaMere M, Stevens BM, et al. Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Blood. 2016;128(13):1671–1678. doi:10.1182/blood-2016-02-69531227421961
   PubMed Web of Science ®Google Scholar
• Lagadinou ED, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12(3):329–341. doi:10.1016/j.stem.2012.12.01323333149
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Stevens BM, Jones CL, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018;24(12):1859–1866. doi:10.1038/s41591-018-0233-130420752
   PubMed Web of Science ®Google Scholar
• Molina JR, Sun Y, Protopopova M, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018;24(7):1036–1046. doi:10.1038/s41591-018-0052-429892070
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Jones CL, Stevens BM, et al. Relapsed acute myeloid leukemia is less sensitive to venetoclax + azacitidine due to leukemia stem cell resistance driven by fatty acid metabolism and can be overcome by pharmacologic inhibition of CPT1. Blood. 2018;132(Suppl 1):432.
   Google Scholar
• Di Nardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93(3):401–407. doi:10.1002/ajh.2500029218851
   PubMed Web of Science ®Google Scholar
• Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–1117. doi:10.1158/2159-8290.CD-16-031327520294
   PubMed Web of Science ®Google Scholar